ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency (EMA). The submission occurred on July 29, 2011.
Amarin Corporation plc (Nasdaq:AMRN) announced today the successful completion of all remaining studies required for its NDA for AMR101 for the treatment of patients with very high triglycerides. It plans to submit an NDA for AMR101 by the end of September.
Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that it has submitted its reply to the Complete Response Letter issued in February 2011 for taliglucerase alfa. Taliglucerase alfa is in development for the treatment of Gaucher disease.